“Rapamycin slows aging in healthy people.”
Limited confidence because a 48-week randomized trial in generally healthy adults found no change in its primary visceral-fat outcome and only selected subgroup or self-reported secondary benefits. It did not measure lifespan or prove that biological aging slowed, and the trial was small, used compounded drug with reduced bioavailability, and had commercial conflicts.
We do not know that rapamycin slows aging in healthy people. A one-year trial found similar adverse-event counts and a few secondary benefits, but no effect on its primary outcome and no evidence of longer life or slower aging.
Rapamycin extends lifespan in several animal models, which makes it a serious research candidate. Animal longevity and a handful of human healthspan measures are not the same as demonstrated slowing of human aging.
Safety note: Rapamycin is a prescription mTOR inhibitor used at higher or more continuous doses for immunosuppression. Possible effects include mouth sores, infection, abnormal lipids or glucose, impaired wound healing and drug interactions; long-term intermittent use in healthy people remains uncertain.
Talk to a healthcare professional if: Do not self-prescribe or use an unverified product. Off-label use requires a prescriber who can review interactions, infection and vaccination issues, planned surgery, symptoms and appropriate laboratory monitoring.
This is a plausible research strategy, but taking rapamycin for longevity today means accepting uncertain benefit and incomplete long-term safety evidence.
Prefer a registered clinical trial. If you are still considering off-label treatment, discuss the evidence and monitoring plan with a clinician who is independent of the seller.